- Home
- IMCC vs KZIA Comparison
IMCC vs KZIA Comparison
Compare IMCC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCC | KZIA |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | IMCC | KZIA |
|---|---|---|
| Price | $1.52 | $10.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 292.2K | ★ 323.3K |
| Earning Date | 11-13-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,606,703.00 | $1,199,108.00 |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.92 | N/A |
| 52 Week Low | $0.93 | $2.86 |
| 52 Week High | $7.12 | $17.40 |
Technical Indicators
Market Signals| Indicator | IMCC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 51.30 |
| Support Level | $1.41 | $8.91 |
| Resistance Level | $1.91 | $12.20 |
| Average True Range (ATR) | 0.23 | 2.36 |
| MACD | -0.01 | -0.46 |
| Stochastic Oscillator | 22.46 | 31.58 |
Price Performance
Historical ComparisonAbout IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.